[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632499":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":58,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Hamad General Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: LISA Group","PLACEBO_COMPARATOR","Administration of exogenous surfactant (Beractant, 100 mg\u002Fkg in 4 mL\u002Fkg) via a thin catheter while the infant is maintained on non-invasive respiratory support (CPAP or NIPPV).",[13],"Procedure: surfactant administration by thin catheter",{"label":15,"type":16,"description":17,"interventionNames":18},"ETT Group","EXPERIMENTAL","Administration of exogenous surfactant (Beractant, 100 mg\u002Fkg in 4 mL\u002Fkg) delivered via an endotracheal tube following intubation, accompanied by brief mechanical ventilation and extubation if feasible.",[19],"Procedure: surfactant administration by ETT",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","surfactant administration by ETT","Administration of exogenous surfactant (Beractant, 100 mg\u002Fkg in 4 mL\u002Fkg) via an endotracheal tube following intubation, accompanied by brief mechanical ventilation and extubation if feasible.",[15],null,{"type":22,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"surfactant administration by thin catheter",[9],[31],"LISA",[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Loay A Alkamel, MD, Mac","CONTACT","0097455190326","lalkamel@hamad.qa",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Women's Wellness and Research Center (WWRC), Hamad Medical Corporation","RECRUITING","Doha","Qatar","QA",{"type":46,"coordinates":47},"Point",[48,49],51.53096,25.28545,{"lat":49,"lon":48},[52,55],{"name":53,"role":35,"phone":36,"phoneExt":26,"email":54},"Loay A Alkamel, MD, Msc","loay.alkamel@gmail.com",{"name":56,"role":57,"phone":26,"phoneExt":26,"email":26},"Husam Salameh, MD","SUB_INVESTIGATOR",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Loay Alkamel","Neonatologist-Clinical Researcher","100632499","lisa-vs-endotracheal-surfactant-in-preterm-neonates-a-lung-ultrasound-distribution-study-100632499",false,"NCT07514481","LISA vs Endotracheal Surfactant in Preterm Neonates: A Lung Ultrasound Distribution Study","A Prospective Pilot Controlled Trial Comparing the Intrapulmonary Distribution of Exogenous Surfactant Between (LISA) and Conventional Endotracheal Intubation in Preterm Neonates With RDS Using Lung Ultrasound and the NOVEL Surfactant Distribution Homogeneity Index (SDHI)","LISA-Ven-LUS","Inclusion Criteria:\n\nGestational age 24+0 to 42+6 weeks. Clinical and radiographic diagnosis of Respiratory Distress Syndrome (RDS). Requirement for surfactant within the first 3 days of life. Written informed parental consent.\n\nExclusion Criteria:\n\nInfants intubated at birth or who received surfactant prophylactically in the delivery room.\n\nMajor congenital anomalies or lung malformations (e.g., congenital diaphragmatic hernia, pulmonary hypoplasia).\n\nSyndromic or genetic conditions affecting lung or chest wall development. Severe hemodynamic instability or congenital heart disease requiring intensive support.\n\nLack of parental consent for trial participation.","ALL","24 Weeks","42 Weeks",{"count":74,"type":75},22,"ESTIMATED","INTERVENTIONAL",[78],"NA","This prospective, non-randomized, unblinded pilot study evaluates and compares the intrapulmonary distribution of exogenous surfactant in preterm neonates when administered via Less Invasive Surfactant Administration (LISA) versus conventional endotracheal intubation (ETT). Lung ultrasound (LUS) will be utilized to assess the pioneer Surfactant Distribution Homogeneity Index (SDHI) to quantify the evenness and extent of surfactant-induced lung aeration. Secondary objectives include evaluating changes in LUS scores, short-term clinical respiratory outcomes, and feasibility parameters for guiding future larger-scale trials.",[81],"Respiratory Distress Syndrome, Newborn",[83],"Less Invasive Surfactant Administration, LISA, Lung Ultrasound, Neonatology, Surfactant Distribution Homogeneity Index","2026-04-01",{"date":86,"type":87},"2026-04-07","ACTUAL",{"date":89,"type":87},"2026-01-01",{"date":91,"type":75},"2026-07-30",{"name":5,"class":6},1]